Who are Methotrexate (stable dose)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Intrathecal Methotrexate, MTX therapy, MTX, Placebo Methotrexate, Methotrexate (tapering dose), Methotrexate (MTX).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/methotrexate-stable-dose.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Methotrexate (stable dose) — Competitive Intelligence Brief

Methotrexate (stable dose) (Methotrexate (stable dose)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimetabolite; Folate antagonist. Area: Oncology; Immunology; Rheumatology.

marketed Antimetabolite; Folate antagonist Dihydrofolate reductase (DHFR) Oncology; Immunology; Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

Methotrexate (stable dose) (Methotrexate (stable dose)) — Hoffmann-La Roche. Methotrexate inhibits dihydrofolate reductase, blocking the synthesis of purines and pyrimidines required for DNA replication and cell division.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Methotrexate (stable dose) TARGET	Methotrexate (stable dose)	Hoffmann-La Roche	marketed	Antimetabolite; Folate antagonist	Dihydrofolate reductase (DHFR)
Intrathecal Methotrexate	Intrathecal Methotrexate	Sun Yat-sen University	marketed	Antimetabolite; folate antagonist	Dihydrofolate reductase (DHFR)
MTX therapy	MTX therapy	NYU Langone Health	marketed	Folate antagonist / Antimetabolite	Dihydrofolate reductase (DHFR)
MTX	MTX	South China Children's Leukemia Group	marketed	Antimetabolite; folate antagonist	Dihydrofolate reductase (DHFR)
Placebo Methotrexate	Placebo Methotrexate	AbbVie	marketed	Folate antagonist / Antimetabolite	Dihydrofolate reductase (DHFR)
Methotrexate (tapering dose)	Methotrexate (tapering dose)	Hoffmann-La Roche	marketed	Antimetabolite / Folate antagonist	Dihydrofolate reductase (DHFR)
Methotrexate (MTX)	Methotrexate (MTX)	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh	marketed	Antimetabolite; folate antagonist	Dihydrofolate reductase (DHFR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimetabolite; Folate antagonist class)

Centocor, Inc. · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
JHSPH Center for Clinical Trials · 1 drug in this class
University Hospital, Bordeaux · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Methotrexate (stable dose) — Competitive Intelligence Brief. https://druglandscape.com/ci/methotrexate-stable-dose. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab